SQI Diagnostics Inc V.SQD.H

Martine Rothblatt & Shaf Keshavjee working hand in hand.

[FactFinder1994]

The vision is becoming a reality. When Toronto General Hospital opened the first organ repair center in 2008, it caught the attention of Martine Rothblatt, founder and chairwoman of United Therapeutics (UT), which develops treatments for lung disease. “Martine called me up and said she wanted to build a lung repair hospital,” says Keshavjee, who consults for UT. A year later, the center was up, run by UT subsidiary Lung Biotechnology. The first case study of remote EVLP, published in 2012, involved a 54-year old man, in Chicago, whose acute respiratory distress syndrome was rapidly proving fatal9. The only set of organs available at the time were poorly oxygenated, with edema and infiltrate (blood, pus or other proteins) filling part of the right lower lobe. The lungs were sent by air, under standard cold-flush preservation, from the donor hospital to Toronto General Hospital for four hours of EVLP. Then they were flown, cold, to Chicago and transplanted. The second period of cold ischemia seemed to have no adverse effect, according to the study's authors.

Keshavjee's team at Toronto is progressing toward a 30-minute, nanochip-based test to diagnose a series of genes expressed in lung tissue that may predict transplant success. These include genes encoding inflammatory cytokines like interleukin (IL)-1 beta, IL-6 and IL-8, which are upregulated in transplanted organs, and more that he isn't disclosing. “Ultimately, we hope to have a score to determine which lungs to transplant,” says Keshavjee.

Inflammation is a key part of the recipient immune response that causes many organ transplants to fail. Even in successful cases, recipients must take immune suppressants for the rest of their lives. Perfusion technology may reduce or even eliminate this need, by better preparing the organ immunologically. Keshavjee and his University of Toronto colleague Marcelo Cypel, associate professor of thoracic surgery and developer of the Toronto EVLP protocol, are exploring the use of gene therapy to program cells to continue to express IL-10, an anti-inflammatory cytokine.

SQI's TOR-Dx is the test providing the score!  Hundred Million dollar market as part of the protocol where there are no others welcome.  UHN-Shaf Keshavjee's protocols are followed all over the world and growing.  The footprints are already established...
 
Beating the organ clockNature Journalhttps://www.nature.com › ... › news feature